A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed And/or Refractory B-Cell MalignanciesIrit Avivi Mazza,Pere Barba,Junichiro Yuda,Maria Lia Palomba,Juan Pablo Alderuccio,Ciel de Vriendt,Paolo Corradini,Francesca Lorraine Wei Inng Lim,Pier Luigi Zinzani,Nitin Jain,Jessica T. Leonard,Michelle Coulson,Nadia Hassounah, Xiaoling Yang,Haihui Lu,Andrew Lewandowski,Joseph Ryan Polli, Matthieu Klopfenstein,Alessandro Pastore,Gabriel BrisouBlood（2023）引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
